This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $433,583 to the University of Nebraska Medical Center (UNMC) for research aimed at characterizing the mechanisms by which the molecular scaffold KSR1 regulates tumor initiation, drug resistance, and the epithelial-to-mesenchymal transition (EMT) in colorectal cancer. The research will utilize genetically modified colorectal cancer organoids, mouse models, and cell lines to investigate how KSR1-dependent signaling and splicing pathways influence the behavior of tumor-initiating cells and promote their transition to an invasive, mesenchymal state. The award, effective May 1, 2024 through Apr 30, 2029, includes a sub-award to the Jackson Laboratory to provide specialized research support. The overall goal is to reveal novel mechanisms that can be targeted to improve therapeutic response and inhibit tumor initiation and metastasis in colorectal cancer.
Generated 1/28/25, 10:27 AM